PMID: 10469335[PubMed Reference] Philp D, Badamchian M, Scheremeta B, et al
Niraparib showed promising activity in preclinical models and phase I clinical trials, achieving its pharmacodynamic target for PARP inhibition in epithelial ovarian cancer, particularly in patients who have responded to platinum-based chemotherapy 167 (Fig
The vast majority of patients who take Accutane for severe acne only experience mild side effects that may cause some discomfort but can be relatively easily addressed and do not cause any lasting damage to the body
Nutr Biochem 1997;8:660-672 5
At Acton and Canton Urgent Care, we typically recommend IV therapy every two to four weeks for most healthy individuals seeking overall wellness, immune support, or hydration
Their mechanisms of action are completely different, focusing on cellular repair and signaling pathways